e15587 Background: NGS-based mutation profiling is increasingly used to guide oncology treatment. This study compares comprehensive genomic profiling (CGP) with limited panels 116/1100) with M:F ratio 1.9:1 commonly involved primary sites were sigmoid colon (n = 46) comutation commonly observed were KRAS + TP53 ( n = 18) common chemotherapy regimens were FOLFOX (n = 43) & CAPOX (n = 31). Targeted therapy was administered in first line to 19.8% (n = 22/111) mostly: Bevacizumab (n = 18), Cetuximab (n = 5) & regorafenib (n = 2) with 77.3% ORR. Immunotherapy was administered to 6% (7/116) with distribution: Pembrolizumab (n = 3), Nivolumab(n = 2) Dostarlimab (n = 1), Atezolizumab (n = 1) & 50% CBR. Among first line recipients, best responses were complete response in 30.6%, partial response in 33.3% & stable disease in 3.6%. Median overall survival (mOS) was 21.4 mo in BRAF mutant cohort vs 49.5 mo in other mutations (p = 0.035). mOS for NRAS/KRAS mutant cohort was 28.8 mo vs not reached in others (p = 0.032). TP53 mutant cases had mOS of 28.8 mo vs 49.5 mo in non-mutants (p = 0.191). mOS was not reached in immunotherapy marker mutant patients vs 49.5 mo in non-mutants (p = 0.091). Conclusions: This study supports CGP as a clinically impactful tool in precision oncology emphasizing its importance & improving its integration and accessibility in resource-limited healthcare settings.
Sethjiwala et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: